Compare MPLX LP (MPLX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Merck & Co., Inc. — how do they compare? MPLX LP trades at $56.3 (market cap $58.11B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 6× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| MPLX | MRK | |
|---|---|---|
Market Cap | $58.11B | $351.28B |
Volume | 687,483 | 7,969,665 |
Sector | Energy | Health |
52-Week High | $60.51 | $156.43 |
52-Week Low | $47.80 | $82.49 |
Enterprise Value | $83.22B | $398.04B |
Dividend Yield | 7.51% | 2.39% |
Typical Hold Time | — | 98 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.30, down 1.31% today, with a bearish technical signal and mixed earnings history including a recent Q2 2026 EPS miss. The company maintains strong profitability with a 40.45% net income margin and robust cash flow, supporting a $1.08 dividend. Analyst consensus is bullish with a $63.80 price target, though technical indicators show near-term resistance at $58.
The outlook for MPLX is positive due to its fee-based revenue model, high dividend yield, and analyst support, but risks include energy market volatility and recent earnings misses. Investors may find value in its cash flow stability, though caution is warranted given bearish technical trends and macroeconomic pressures on the energy sector.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
